compounding semaglutide enforcement news today glp-1 november 2025 fda The FDA has released new guidance for providers prescribing GLP-1 Shortage = Over Weight loss drugs and compounding

Daewoong Pharmaceutical is poised to enter this market with its innovative microneedle obesity treatment by 2028, aiming to revolutionize the sector by addressing the limitations of current therapies, especially in improving treatment adherencea significant challenge highlighted by Eli Lilly's CSO, Dr

Why this matters on GLP-1s - Appetite is lower, so each serving needs to be more efficient - Higher leucine helps stimulate muscle maintenance even with smaller portions - Often requires less total volume to meet protein targets Common animal-based options - Whey isolate - Egg protein - Casein Considerations - Some individuals experience digestive discomfort while on GLP-1s - Dairy-based proteins may not be tolerated by everyone - Flavor and texture can feel heavy during appetite suppression Animal proteins tend to work well for individuals prioritizing muscle preservation, resistance training, and efficiency per serving

It is a trap

Gaps: dosing, delivery, safety, and large RCTs remain

The discounted GLP-1 net price for state Medicaid programs will be available through additional supplemental rebates (on top of statutory rebates through the MDRP)